
If you are in the market for some new portfolio additions, then it could be worth hearing what Morgans is saying about the shares in this article.
That’s because the broker recently named all three ASX 200 shares as buys. Here’s what you need to know:
Magellan Financial Group Ltd (ASX: MFG)
This fund manager could be worth considering according to the broker. It believes the merger with Barrenjoey is a game-changer and provides “additional pathways for growth.”
Morgans has put a buy rating and $11.99 price target on Magellan’s shares. It said:
MFG has given an end-to-March 2026 quarterly FUM update. FUM (A$37.5bn) was down 6% for the quarter due to a combination of outflows across most funds and market movements. Overall this was a softer quarter at the headline level, albeit some impacts from market volatility are unsurprising. We downgrade our MFG FY26F/FY27F EPS by -1%/-8% due to slightly weaker FUM assumptions and also applying more conservatism to our future Barrenjoey earnings forecasts.
Our PT falls to A$11.99 (from A$12.43). Whilst MFG’s Investment Management performance remains patchy, we think the Barrenjoey merger fundamentally changes MFG’s overall outlook, strengthening the business and providing additional pathways for growth. MFG also retains a strong balance sheet (~A$650m of liquidity, post deal). BUY maintained.
Nufarm Ltd (ASX: NUF)
Another ASX 200 share that has been given the thumbs up is agricultural chemicals company Nufarm.
In response to a better-than-expected performance in FY 2026, the broker put a buy rating and $4.05 price target on its shares. It said:
Pleasingly, NUF’s 1H26 EBITDA guidance was slightly higher than expected and it has had a strong 1H. Importantly, its leverage guidance is materially better than expected. Initial outlook comments for the 2H26 were positive and a new A$50m cost out program has been announced.
Given the appreciation in active ingredient and fish oil prices, NUF’s previous FY26 guidance could prove to be conservative. NUF is our key pick of the ag and chemical sector. The company is materially undervalued and we reiterate our BUY rating with a new price target of A$4.05.
Sigma Healthcare Ltd (ASX: SIG)
Morgans is also bullish on Chemist Warehouse owner Sigma Healthcare.
Due to its strong growth outlook and recent share price weakness, the broker has put a buy rating and $3.36 price target on the ASX 200 share. It explains:
SIG is a leading healthcare wholesaler, distributor and retail pharmacy franchisor with operations in Australia, NZ, Ireland and the UAE. We are forecasting ~20% EBIT growth p.a. over the next few years driven by strong LFL sales growth, store rollout (domestically and internationally), operating efficiencies and $100m p.a. synergies by FY29. Given the share price weakness, we have upgraded our recommendation to BUY (from ACCUMULATE) with an unchanged target price of $3.36 and 26% upside.
The post Morgans names 3 ASX 200 shares to buy now appeared first on The Motley Fool Australia.
Should you invest $1,000 in Magellan Financial Group right now?
Before you buy Magellan Financial Group shares, consider this:
Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Magellan Financial Group wasn’t one of them.
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
And right now, Scott thinks there are 5 stocks that may be better buys…
* Returns as of 20 Feb 2026
.custom-cta-button p {
margin-bottom: 0 !important;
}
More reading
- 2 top ASX shares to buy and hold for the next decade
- I think these are some of the best ASX 200 shares to buy now
- If I had $5,000 to invest in ASX 200 shares today, here’s what I’d buy
- Buy, hold, sell: Evolution Mining, Netwealth, and Nufarm shares
- Why this ASX 200 share could be heading 40%+ higher
Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.